Oluwaseun Odewole MD, MPH, Presenter: Nothing to Disclose

Funmilayo Tade MD, MPH, Abstract Co-Author: Nothing to Disclose

Oyeladun Oyenuga MD, MPH, Abstract Co-Author: Nothing to Disclose

Bital Savir-Baruch MD, Abstract Co-Author: Nothing to Disclose

Ashesh B. Jani MD, Abstract Co-Author: Nothing to Disclose

Osunkoya Adeboye MD, Abstract Co-Author: Nothing to Disclose

Raghuveer K. Halkar MD, Abstract Co-Author: Research Grant, General Electric Company Research Grant, Gilead Sciences, Inc Royalties, General Electric Company

Peter Nieh MD, Abstract Co-Author: Nothing to Disclose

Viraj Master MD, Abstract Co-Author: Nothing to Disclose

Mark M. Goodman PhD, Abstract Co-Author: Royalties, Nihon Medi-Physics Co, Ltd

David M. Schuster MD, Abstract Co-Author: Research funded, Nihon Medi-Physics Co, Ltd Expert Advisory Committee, AIM Specialty Health

To compare the diagnostic performance of the synthetic amino acid analog PET radiotracer anti-3-[18F] FACBC (FACBC) with computed tomography (CT) in the detection of recurrent prostate carcinoma.

86 patients with suspected recurrent prostate carcinoma after definitive therapy for localized disease and negative bone scan underwent routine diagnostic CT scan and FACBC PET-CT. Correlation to ground truth was made to histology and clinical followup by a multidisciplinary board. Diagnostic performance and scan positivity rates were calculated for both FACBC PET-CT and CT.

83 out of 86 (97%) patients and 67 out of 86 (78%) patients had a reference standard sufficient to determine the presence of prostatic or extraprostatic disease respectively. Mean PSA (±SD) was 6.7 (±6.3) ng/ml. 70 of 86 (81.4%) FACBC scans versus 16 of 86 (18.6%) CT examinations had positive findings suspicious for recurrent disease. At a PSA <1 ng/ml, scan positivity rate for FACBC was 38.5% and CT was 7.7%, while for PSA ≥ 1 scan positivity rate for FACBC was 89.0% and CT was 20.5%. In the prostate bed, FACBC correctly identified 40 more true positive patients than CT (47 vs 7) with a sensitivity of 90.4% for FACBC compared with a sensitivity of 13.2% for CT and a similar positive predictive value (PPV) of 71.2% and 70.0%, respectively [Table1]. For extra-prostatic disease detection, FACBC correctly identified 16 more true positive patients than CT (21 vs 5) with sensitivity of 51.2% for FACBC compared with a sensitivity of 12.5% for CT and a similar PPV of 95.5% and 100%, respectively [Table 1].  

Anti-3-[18F]FACBC detects more patients with recurrent prostate cancer than CT scan and can better delineate prostatic from extra-prostatic recurrence.

Anti-3-[18F]FACBC is useful for restaging of patients with suspected prostate cancer recurrence.

Odewole, O, Tade, F, Oyenuga, O, Savir-Baruch, B, Jani, A, Adeboye, O, Halkar, R, Nieh, P, Master, V, Goodman, M, Schuster, D, Recurrent Prostate Cancer Detection with Anti-3-[18F] FACBC PET-CT: Comparison with CT.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007958.html